Regencell controller holds options on 740,278 shares

Regencell Bioscience Holdings Ltd filed an initial ownership report for its Financial Controller, Chan Ho Yau, showing a stock option position.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd filed an initial ownership report for its Financial Controller, Chan Ho Yau, showing a stock option position. The option covers 740,278 underlying ordinary shares at an exercise price of $0.2500 per share. It was granted on June 9, 2021 under the 2021 Share Option Plan, vested in four equal installments on each anniversary of the company’s initial public offering closing, is now fully vested, and will expire 10 years after the options become vested.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CHAN HO YAU

Role Financial Controller

Type	Security	Shares	Price	Value
holding	Stock option (right to purchase)	--	--	--

Holdings After Transaction: Stock option (right to purchase) — 740,278 contracts (Direct)

Footnotes (1)

F1. The Reporting Person was granted the option on June 9, 2021 pursuant to the Issuer's 2021 Share Option Plan. The option vested equally each of the four anniversaries of the closing of the Issuer's initial public offering and is now fully vested. The expiration date is 10 years from the date the options become vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider holdings does Regencell Bioscience (RGC) Financial Controller report on this Form 3?

The Financial Controller, Chan Ho Yau, reports a stock option covering 740,278 underlying ordinary shares. This option represents his derivative equity position in Regencell Bioscience and is held directly, according to the insider ownership disclosure.

What is the exercise price of the Regencell Bioscience (RGC) stock option reported?

The reported stock option has an exercise price of $0.2500 per underlying ordinary share. This means Chan Ho Yau can purchase Regencell Bioscience shares at that fixed price once he chooses to exercise the fully vested option.

When was the Regencell Bioscience (RGC) option to Chan Ho Yau granted and how did it vest?

The option was granted on June 9, 2021 under Regencell Bioscience’s 2021 Share Option Plan. It vested in four equal installments on each of the four anniversaries of the closing of the company’s initial public offering and is now fully vested.

When do the stock options reported by Regencell Bioscience (RGC) Financial Controller expire?

The footnote states the options will expire 10 years from the date the options become vested. This provides a long exercise window for Chan Ho Yau to convert his stock option into Regencell Bioscience ordinary shares.

Are the Regencell Bioscience (RGC) options held directly or indirectly by the Financial Controller?

The filing shows the stock option position is held directly by Chan Ho Yau. The ownership code is listed as “D” for direct ownership, with no indication of a trust, partnership, or other indirect holding entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 09:15 AM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CHAN HO YAU

(Last)

(First)

(Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City)

(State)

(Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Financial Controller

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to purchase)	⁽¹⁾	⁽¹⁾	Ordinary shares, par value $0.00001	740,278	$0.25	D

Explanation of Responses:

1. The Reporting Person was granted the option on June 9, 2021 pursuant to the Issuer's 2021 Share Option Plan. The option vested equally each of the four anniversaries of the closing of the Issuer's initial public offering and is now fully vested. The expiration date is 10 years from the date the options become vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Wai Hong Chung, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR